E-Learning

On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and when autologous vein graft is not feasible. Symvess, or the ATEV, is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for arterial replacement and repair. Also Read: Delay Hits Humac

On Friday, China’s central bank, the People’s Bank of China (PBOC), decided to maintain its main benchmark lending rates amid efforts to support economic growth while managing a weakening yuan. The one-year loan prime rate (LPR) remains at 3.1%, while the five-year LPR is steady at 3.6%, influencing corporate loans, household lending, and mortgages. This decision aligned with expectations from a Reuters poll of 27 economists, CNBC reports. Also Read: Amazon’s Project Kuiper In Talks With Taiwan

Slight upward revision to forecast comes in spite of mixed picture in regional markets.

The council expressed concerns about firms’ capacity to deliver high-quality audits, particularly as audit fees rise.

The benchmark US stock measures were tracking in the red before Friday's open as traders await the p

News of the day for Dec. 20, 2024

Using InvestCloud's APL platform, the PMA provides a centralised point for holding, and rebalancing alternative investments.

Investors are expecting more gains for the U.S. stock market in 2025 after two straight standout years, fueled by a solid economy supporting corporate profits, moderating interest rates and pro-growth policies from incoming president Donald Trump. The benchmark S&P 500 is up over 23% year-to-date, even with a recent speed bump, and is on pace for its second straight year of gains exceeding 20%, lifted by megacap tech stocks and excitement over the business potential of artificial intelligence. Investors are more confident about the economy than this time a year ago, with consumers and businesses having absorbed higher interest rates and the Federal Reserve now lowering them - albeit by not as much as hoped.

Political chaos in Washington has stocks on pace for their worst week of the year.

Over the past several years there has been increased public discussion of manufacturing, particularly of ‘reshoring’ in the manufacturing sector. The consensus is that a sector-wide move in that direction is necessary, to reverse the effects of previous decades when much of the US manufacturing plant was moved abroad, to Mexico or East Asia. While reshoring remains more of a policy conversation than a full-scale movement, it has nonetheless influenced recent federal elections. It’s no coincidenc